Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9460248 | 0.89 | NPC1 (0.48) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9176034 | 0.83 | NPC1 (0.41) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL11607664 | 0.83 | NPC1 (0.41) | NPC1RAB9ALMNAALDH1A1KDM4E | |
| SCHEMBL11729209 | 0.82 | RAB9A (0.47) | NPC1RAB9ALMNAALDH1A1POLB | |
| SCHEMBL9621689 | 0.82 | NPC1 (0.42) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9178544 | 0.81 | SMN1; SMN2 (0.41) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9460791 | 0.80 | MYC (0.43) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9460454 | 0.79 | NPC1 (0.39) | NPC1RAB9ALMNASMN1; SMN2MAPK1 | |
| SCHEMBL9460603 | 0.78 | CYP3A4 (0.40) | NPC1RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL9180997 | 0.77 | NPC1 (0.43) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351944-A1 | METHOD FOR PREPARING 2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE | LG Chem Ltd. (KR) | 2003-10-15 | — | — | EP | disclosed |
| US-6559316-B2 | Reacting o-nitrophenylazohydroxyphenyl compound with hydrazine hydrate; reduction in presence of water, zinc powder, and sulfuric acid with/without phase transfer catalyst | LG CHEM, LTD. (KR) | 2003-05-06 | — | — | US | disclosed |
| US-20030050480-A1 | METHOD FOR PREPARING 2-(2-HYRDROXYPHENYL)-2H-BENZOTRIAZOLE | LG CHEM, LTD. (KR) | 2003-03-13 | — | — | US | disclosed |
| WO-2002055508-A1 | METHOD FOR PREPARING 2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE | LG CHEM, LTD. (KR) | 2002-07-18 | — | — | WO | disclosed |
| EP-0380840-B1 | Method of preparing 2-phenylbenzotriazoles | CHEMIPRO KASEI KAISHA LTD (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-5262541-A | Reaction with sugar as a reducing agent | FAIRMONT CHEMICAL COMPANY, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5218139-A | Prostaglandins; treating allergies, autoimmune disorders | G. D. SEARLE & CO. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5157052-A | Administering a prostaglandin | MONSANTO COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0494063-A2 | Method for inhibiting IgE production | MONSANTO COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0263905-B1 | METHOD FOR PREPARING 2-PHENYLBENZOTRIAZOLES AND 2-PHENYLBENZOTRIAZOLE-N-OXIDES | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0160246-B1 | A METHOD FOR PRODUCING A 2-PHENYLBENZOTRIAZOLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
| US-4835284-A | Method for preparing 2-phenylbenzotriazoles and 2-phenylbenzotriazole-N-oxides | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4780541-A | Method for preparing 2-phenylbenzotriazoles and 2-phenylbenzotriazole-N-oxides | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0263905-A1 | Method for preparing 2-phenylbenzotriazoles and 2-phenylbenzotriazole-N-oxides | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0259530-A1 | Method for preparing 2-phenylbenzotriazoles and 2-phenylbenzotriazole-N-oxides | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0257151-A1 | Method for preparing 2-phenylbenzotriazoles and 2-phenylbenzotriazole-N-oxides | CHEMIPRO KASEI KAISHA, LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
| EP-0160246-A1 | A method for producing A 2-phenylbenzotriazole | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-06 | — | — | EP | disclosed |
| US-4220788-A | Process for the preparation of 2-aryl-2H-benzotriazoles | CIBA-GEIGY CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4089839-A | STABILIZERS/AGENTS | UNIROYAL, INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-3978074-A | CATALYTIC HYDROGENATION | UNIROYAL INC. (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050480-A1 | METHOD FOR PREPARING 2-(2-HYRDROXYPHENYL)-2H-BENZOTRIAZOLE | CYP8B1, CYP4Z1, CBR1 | NPC1 1433/4885RAB9A 4742/4885LMNA 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.